Rapid Gonorrhea Test Kits market<\/a>, the market enters 2026 with broader demand fundamentals, more disciplined procurement behavior, and a more regionally diversified supply architecture.<\/p>\nThe World market for Rapid Gonorrhea Test Kits is projected to expand at a high single-digit compound annual growth rate through 2035, driven largely by the global decentralization of sexual health services and the urgent public health imperative to combat antimicrobial resistance in Neisseria gonorrhoeae. Molecular point-of-care (POC) platforms are emerging as the highest-growth sub-segment, capturing an increasing share of procurement value as sensitivity expectations shift toward parity with laboratory-based nucleic acid amplification tests. Regulatory barriers, particularly the EU In Vitro Diagnostic Regulation (IVDR) transition and the stringent CLIA waiver process in the United States, are reshaping the competitive landscape by consolidating market access among well-capitalized multinational suppliers. Dual-market integration of Chlamydia trachomatis and Neisseria gonorrhoeae (CT\/NG) detection in single rapid kits has become the standard procurement requirement, with over 70% of public tenders for rapid gonorrhea tests specifying co-detection capability. Digital connectivity and mobile-reader integration are transitioning from premium features to baseline expectations, enabling real-time surveillance data capture and quality assurance in decentralized testing environments. Self-collection and home-testing protocols are gaining regulatory acceptance, expanding the addressable World market beyond traditional clinical settings and into direct-to-consumer and telehealth-facilitated channels. The inherent sensitivity gap of lateral flow immunoassays relative to laboratory NAAT remains a structural limitation, constraining adoption in high-throughput screening programs where test performance is paramount. Cold chain and ambient stability requirements for reagent shippin<\/p>\n
The baseline scenario for the World Rapid Gonorrhea Test Kits market assumes steady macroeconomic growth, continued public health investment in sexually transmitted infection (STI) control, and gradual regulatory harmonization for point-of-care diagnostics. Under this scenario, the market is forecast to grow from a 2025 base of approximately USD 1.2 billion to over USD 2.5 billion by 2035, reflecting a compound annual growth rate (CAGR) of 7.8%. The market index (2025=100) is projected to reach 210 by 2035. Key assumptions include: sustained WHO and CDC recommendations for expanded gonorrhea screening, particularly among high-risk populations; increasing adoption of multiplex CT\/NG rapid tests in decentralized settings; and gradual replacement of lateral flow immunoassays with molecular POC platforms in higher-volume segments. The baseline also factors in moderate pricing erosion in commoditized test kit segments, offset by value growth in premium molecular and digital-reader-enabled products. Regional dynamics show Asia-Pacific capturing the largest share of absolute growth, driven by large-scale screening programs in China and India, while North America remains the highest-value market per capita due to higher reimbursement rates and rapid adoption of CLIA-waived molecular tests. Europe’s growth is tempered by IVDR compliance costs but supported by national STI action plans. Latin America and Middle East & Africa grow from a smaller base, with donor-funded procurement shaping demand patterns. The baseline does not assume a major disruptive technology shift or a global health emergency that would dramatically accelerate or decelerate adoption, but it does incorporate a gradual improvement in test sensitivity for lateral flow formats, narrowing the gap with laboratory N<\/p>\n
Demand Drivers and ConstraintsPrimary Demand DriversGlobal decentralization of sexual health services and expansion of point-of-care testingUrgent public health imperative to combat antimicrobial resistance in Neisseria gonorrhoeaeStandardization of CT\/NG co-detection in public tenders, driving demand for multiplex rapid kitsRegulatory acceptance of self-collection and home-testing protocols, expanding addressable marketDigital connectivity and mobile-reader integration enabling real-time surveillance and quality assuranceIncreasing WHO and CDC screening recommendations for high-risk populationsPotential Growth ConstraintsInherent sensitivity gap of lateral flow immunoassays relative to laboratory NAAT, limiting adoption in high-throughput screeningCold chain and ambient stability requirements for reagent shipping and storage, increasing total cost of ownership in remote settingsIntense pricing pressure in donor-funded procurement markets, commoditizing standard-grade kit segmentsRegulatory barriers such as EU IVDR transition and CLIA waiver process, consolidating market access among large suppliersLimited reimbursement coverage for rapid tests in some national health systems, slowing adoptionDemand Structure by End-Use IndustryClinical Diagnostics (Hospitals & Laboratories) (estimated share: 40%)<\/p>\n
Clinical diagnostics remains the largest end-use sector, accounting for 40% of market value in 2025. Hospitals and reference laboratories have historically relied on laboratory-based NAAT for gonorrhea detection due to high sensitivity and throughput. However, the trend is shifting toward molecular point-of-care platforms that can deliver results within 30 minutes, reducing patient loss to follow-up. Through 2035, demand in this segment will be driven by the need to reduce turnaround times in emergency departments and STI clinics, particularly for symptomatic patients. Key demand-side indicators include hospital procurement budgets for infectious disease diagnostics, adoption of syndromic management protocols, and the installed base of molecular analyzers capable of running CT\/NG assays. The segment faces pressure from budget constraints in public hospitals, but value growth is supported by premium pricing of multiplex molecular tests that offer both sensitivity and speed. Current trend: Stable growth with shift toward molecular POC platforms.<\/p>\n
Major trends: Integration of CT\/NG co-detection in single rapid test kits, Adoption of molecular POC platforms in hospital emergency departments, Increasing use of digital readers for result documentation and quality assurance, and Shift from batch testing to on-demand testing in decentralized settings.<\/p>\n
Representative participants: Abbott Laboratories, F. Hoffmann-La Roche AG, Cepheid (Danaher Corporation), Becton, Dickinson and Company, and bioM\u00e9rieux SA.<\/p>\n
Point-of-Care Testing (Community Clinics & Outreach) (estimated share: 30%)<\/p>\n
Point-of-care testing is the fastest-growing end-use sector, projected to increase its share from 30% in 2025 to over 35% by 2035. This segment encompasses community health centers, sexual health clinics, mobile testing units, and outreach programs. The demand story is rooted in the global push to decentralize STI testing, reduce time-to-treatment, and reach populations with limited access to laboratory infrastructure. Molecular POC platforms, such as the Binx Health io system and Cepheid GeneXpert, are gaining traction due to their ability to deliver NAAT-equivalent sensitivity in a near-patient setting. Through 2035, growth will be supported by donor-funded programs in low- and middle-income countries, where rapid tests are essential for syndromic management. Key indicators include the number of POC testing sites, procurement volumes from global health organizations, and regulatory approvals for CLIA-waived molecular tests. The segment is price-sensitive, but value growth is driven by volume expansion and the shift toward higher-margin molecular tests. Current trend: High growth driven by decentralization and home-testing expansion.<\/p>\n
Major trends: Expansion of self-collection and home-testing protocols, Integration of mobile-reader technology for data capture and connectivity, Increasing use of multiplex CT\/NG tests in community settings, and Growth of telehealth-facilitated testing and direct-to-consumer channels.<\/p>\n
Representative participants: Binx Health Ltd, Cepheid (Danaher Corporation), QuidelOrtho Corporation, Chembio Diagnostics (Sekisui Diagnostics), and Trinity Biotech plc.<\/p>\n
Public Health & Screening Programs (estimated share: 15%)<\/p>\n
Public health and screening programs account for 15% of market value, driven by national STI control initiatives and donor-funded campaigns. This segment is characterized by large-volume procurement, often through competitive tenders with stringent price caps. Demand is concentrated in countries with high gonorrhea prevalence, such as South Africa, Brazil, and parts of Southeast Asia. Through 2035, growth will be moderate as programs expand screening coverage, but pricing pressure will limit value growth. The shift from lateral flow immunoassays to molecular POC tests is slower here due to cost constraints, but some programs are adopting molecular tests for high-risk populations. Key demand-side indicators include government health budgets for STI control, WHO and CDC funding allocations, and the number of screening campaigns. The segment is highly sensitive to donor funding cycles, with fluctuations in procurement volumes from organizations like the Global Fund and PEPFAR. Current trend: Moderate growth with focus on cost-effectiveness and high throughput.<\/p>\n
Major trends: Adoption of multiplex CT\/NG tests in screening algorithms, Use of digital readers for quality assurance and surveillance data, Integration of rapid tests into syndromic management protocols, and Focus on cost-effectiveness and total cost of ownership.<\/p>\n
Representative participants: Abbott Laboratories, Cepheid (Danaher Corporation), bioM\u00e9rieux SA, and Meridian Bioscience Inc.<\/p>\n
Home Testing & Direct-to-Consumer (estimated share: 10%)<\/p>\n
Home testing and direct-to-consumer (DTC) channels represent the smallest but fastest-growing end-use sector, with a 10% share in 2025 projected to double by 2035. This segment includes self-collection kits sold through pharmacies, online platforms, and telehealth services. The demand story is driven by increasing consumer preference for privacy and convenience, regulatory acceptance of self-collection for gonorrhea testing, and the expansion of telehealth platforms that offer test ordering and result interpretation. Through 2035, growth will be supported by FDA and CE-mark approvals for home-use rapid tests, partnerships between diagnostic companies and digital health platforms, and rising awareness of STI self-testing. Key indicators include the number of DTC test kit launches, telehealth consultation volumes, and consumer adoption rates. The segment faces challenges related to test sensitivity, user error, and regulatory hurdles, but value growth is high due to premium pricing of DTC kits and subscription models. Current trend: Rapid growth from a small base, driven by regulatory acceptance and telehealth.<\/p>\n
Major trends: Regulatory approvals for self-collection and home-use rapid tests, Integration with telehealth platforms for result interpretation and treatment referral, Rise of subscription-based STI testing services, and Use of mobile apps for test result reading and data sharing.<\/p>\n
Representative participants: QuidelOrtho Corporation, Binx Health Ltd, LetsGetChecked (private), Everlywell (private), and myLAB Box (private).<\/p>\n
Research & Academic Institutions (estimated share: 5%)<\/p>\n
Research and academic institutions account for 5% of market value, driven by demand for rapid gonorrhea test kits in epidemiological studies, clinical trials, and assay development. This segment includes universities, research hospitals, and public health institutes that use rapid tests for surveillance, vaccine trials, and diagnostic validation. Through 2035, growth will be steady, supported by increased funding for STI research, particularly around antimicrobial resistance and vaccine development. Key demand-side indicators include research grant allocations, number of clinical trials for gonorrhea vaccines and therapeutics, and publications using rapid test data. The segment is less price-sensitive than public health programs, with demand driven by test performance and flexibility. However, it is a small volume segment, and growth is tied to research funding cycles. Current trend: Stable growth with focus on assay development and epidemiological studies.<\/p>\n
Major trends: Use of rapid tests in antimicrobial resistance surveillance studies, Integration of rapid tests into vaccine efficacy trials, Development of next-generation multiplex assays for research use, and Collaboration between academic institutions and diagnostic companies for assay validation.<\/p>\n
Representative participants: F. Hoffmann-La Roche AG, Hologic Inc, Siemens Healthineers AG, and Becton, Dickinson and Company.<\/p>\n
Key Market Participants<\/p>\n
Interactive table based on the Store Companies dataset for this report.<\/p>\n
\t\t\t\tSort: Rank
\n\t\t\t\tSort: Company A-Z
\n\t\t\t\tSort: Headquarters A-Z<\/p>\n
\t\t\t\t\t#
\n\t\t\t\t\tCompany
\n\t\t\t\t\tHeadquarters
\n\t\t\t\t\tFocus
\n\t\t\t\t\tScale
\n\t\t\t\t\tNote<\/p>\n
\t\t\t\t\t\t1
\n\t\t\t\t\t\tAbbott Laboratories
\n\t\t\t\t\t\tAbbott Park, Illinois, USA
\n\t\t\t\t\t\tDiagnostics & rapid testing
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tKey player in point-of-care STD testing<\/p>\n
\t\t\t\t\t\t2
\n\t\t\t\t\t\tRoche Diagnostics
\n\t\t\t\t\t\tBasel, Switzerland
\n\t\t\t\t\t\tMolecular diagnostics & rapid tests
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tOffers cobas systems for gonorrhea detection<\/p>\n
\t\t\t\t\t\t3
\n\t\t\t\t\t\tCepheid
\n\t\t\t\t\t\tSunnyvale, California, USA
\n\t\t\t\t\t\tMolecular rapid testing
\n\t\t\t\t\t\tLarge subsidiary of Danaher
\n\t\t\t\t\t\tGeneXpert platform includes gonorrhea test<\/p>\n
\t\t\t\t\t\t4
\n\t\t\t\t\t\tBio-Rad Laboratories
\n\t\t\t\t\t\tHercules, California, USA
\n\t\t\t\t\t\tDiagnostic test kits
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tProvides rapid gonorrhea antigen tests<\/p>\n
\t\t\t\t\t\t5
\n\t\t\t\t\t\tHologic, Inc.
\n\t\t\t\t\t\tMarlborough, Massachusetts, USA
\n\t\t\t\t\t\tWomen’s health diagnostics
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tAptima Combo 2 assay for gonorrhea<\/p>\n
\t\t\t\t\t\t6
\n\t\t\t\t\t\tSiemens Healthineers
\n\t\t\t\t\t\tErlangen, Germany
\n\t\t\t\t\t\tDiagnostic imaging & lab testing
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tOffers rapid gonorrhea test kits<\/p>\n
\t\t\t\t\t\t7
\n\t\t\t\t\t\tBecton Dickinson (BD)
\n\t\t\t\t\t\tFranklin Lakes, New Jersey, USA
\n\t\t\t\t\t\tDiagnostic systems & rapid tests
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tBD Veritor system for gonorrhea<\/p>\n
\t\t\t\t\t\t8
\n\t\t\t\t\t\tThermo Fisher Scientific
\n\t\t\t\t\t\tWaltham, Massachusetts, USA
\n\t\t\t\t\t\tLab equipment & diagnostics
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tSupplies rapid gonorrhea test components<\/p>\n
\t\t\t\t\t\t9
\n\t\t\t\t\t\tMerck KGaA (EMD Millipore)
\n\t\t\t\t\t\tDarmstadt, Germany
\n\t\t\t\t\t\tLife science & diagnostics
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tProvides reagents for gonorrhea testing<\/p>\n
\t\t\t\t\t\t10
\n\t\t\t\t\t\tQuidelOrtho Corporation
\n\t\t\t\t\t\tSan Diego, California, USA
\n\t\t\t\t\t\tRapid diagnostic tests
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tSofia 2 analyzer for gonorrhea<\/p>\n
\t\t\t\t\t\t11
\n\t\t\t\t\t\tDiaSorin S.p.A.
\n\t\t\t\t\t\tSaluggia, Italy
\n\t\t\t\t\t\tImmunodiagnostics & molecular tests
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tLiaison platform for gonorrhea<\/p>\n
\t\t\t\t\t\t12
\n\t\t\t\t\t\tbioM\u00e9rieux SA
\n\t\t\t\t\t\tMarcy-l’\u00c9toile, France
\n\t\t\t\t\t\tIn vitro diagnostics
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tBioFire FilmArray includes gonorrhea panel<\/p>\n
\t\t\t\t\t\t13
\n\t\t\t\t\t\tSekisui Diagnostics
\n\t\t\t\t\t\tTokyo, Japan
\n\t\t\t\t\t\tRapid test kits
\n\t\t\t\t\t\tLarge multinational
\n\t\t\t\t\t\tOffers gonorrhea rapid antigen tests<\/p>\n
\t\t\t\t\t\t14
\n\t\t\t\t\t\tACON Laboratories
\n\t\t\t\t\t\tSan Diego, California, USA
\n\t\t\t\t\t\tPoint-of-care rapid tests
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tFlow-through gonorrhea test kits<\/p>\n
\t\t\t\t\t\t15
\n\t\t\t\t\t\tChembio Diagnostics (now part of Biosynex)
\n\t\t\t\t\t\tMedford, New York, USA
\n\t\t\t\t\t\tRapid STD tests
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tDPP HIV-Syphilis-Gonorrhea combo test<\/p>\n
\t\t\t\t\t\t16
\n\t\t\t\t\t\tAlere (now Abbott)
\n\t\t\t\t\t\tWaltham, Massachusetts, USA
\n\t\t\t\t\t\tRapid diagnostics
\n\t\t\t\t\t\tLarge (subsidiary)
\n\t\t\t\t\t\tLegacy brand, integrated into Abbott<\/p>\n
\t\t\t\t\t\t17
\n\t\t\t\t\t\tOraSure Technologies
\n\t\t\t\t\t\tBethlehem, Pennsylvania, USA
\n\t\t\t\t\t\tOral fluid diagnostics
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tRapid gonorrhea test in development<\/p>\n
\t\t\t\t\t\t18
\n\t\t\t\t\t\tTrinity Biotech
\n\t\t\t\t\t\tBray, Ireland
\n\t\t\t\t\t\tDiagnostic test kits
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tOffers gonorrhea rapid test strips<\/p>\n
\t\t\t\t\t\t19
\n\t\t\t\t\t\tEiken Chemical Co., Ltd.
\n\t\t\t\t\t\tTokyo, Japan
\n\t\t\t\t\t\tRapid diagnostic tests
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tGonorrhea antigen detection kits<\/p>\n
\t\t\t\t\t\t20
\n\t\t\t\t\t\tNectar Lifesciences Ltd.
\n\t\t\t\t\t\tChandigarh, India
\n\t\t\t\t\t\tPharmaceutical & diagnostics
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tManufactures rapid gonorrhea test kits<\/p>\n
\t\t\t\t\t\t21
\n\t\t\t\t\t\tJ. Mitra & Co. Pvt. Ltd.
\n\t\t\t\t\t\tNew Delhi, India
\n\t\t\t\t\t\tDiagnostic kits
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tRapid gonorrhea test card<\/p>\n
\t\t\t\t\t\t22
\n\t\t\t\t\t\tZhejiang Orient Gene Biotech Co., Ltd.
\n\t\t\t\t\t\tHuzhou, China
\n\t\t\t\t\t\tRapid test manufacturing
\n\t\t\t\t\t\tLarge
\n\t\t\t\t\t\tExports gonorrhea rapid test kits globally<\/p>\n
\t\t\t\t\t\t23
\n\t\t\t\t\t\tHangzhou AllTest Biotech Co., Ltd.
\n\t\t\t\t\t\tHangzhou, China
\n\t\t\t\t\t\tPoint-of-care tests
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tGonorrhea rapid test cassette<\/p>\n
\t\t\t\t\t\t24
\n\t\t\t\t\t\tBeijing Wantai Biological Pharmacy
\n\t\t\t\t\t\tBeijing, China
\n\t\t\t\t\t\tDiagnostic reagents
\n\t\t\t\t\t\tLarge
\n\t\t\t\t\t\tGonorrhea rapid test products<\/p>\n
\t\t\t\t\t\t25
\n\t\t\t\t\t\tSD Biosensor, Inc.
\n\t\t\t\t\t\tSuwon, South Korea
\n\t\t\t\t\t\tRapid diagnostic tests
\n\t\t\t\t\t\tLarge
\n\t\t\t\t\t\tStandard Q gonorrhea test<\/p>\n
\t\t\t\t\t\t26
\n\t\t\t\t\t\tBiopanda Reagents
\n\t\t\t\t\t\tBelfast, UK
\n\t\t\t\t\t\tRapid test kit distribution
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tSupplies gonorrhea test kits to Europe<\/p>\n
\t\t\t\t\t\t27
\n\t\t\t\t\t\tCTK Biotech, Inc.
\n\t\t\t\t\t\tSan Diego, California, USA
\n\t\t\t\t\t\tRapid test manufacturing
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tGonorrhea rapid test strips<\/p>\n
\t\t\t\t\t\t28
\n\t\t\t\t\t\tDiagnostics for the Real World (DRW)
\n\t\t\t\t\t\tSunnyvale, California, USA
\n\t\t\t\t\t\tPoint-of-care molecular tests
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tSAMBA platform for gonorrhea<\/p>\n
\t\t\t\t\t\t29
\n\t\t\t\t\t\tMologic Ltd.
\n\t\t\t\t\t\tBedford, UK
\n\t\t\t\t\t\tRapid diagnostic development
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tGonorrhea lateral flow tests<\/p>\n
\t\t\t\t\t\t30
\n\t\t\t\t\t\tSavyon Diagnostics Ltd.
\n\t\t\t\t\t\tAshdod, Israel
\n\t\t\t\t\t\tInfectious disease diagnostics
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tGonorrhea rapid test kits<\/p>\n
\tRegional DynamicsAsia-Pacific (estimated share: 35%)<\/p>\n
Asia-Pacific holds the largest market share at 35%, driven by high gonorrhea prevalence, large-scale screening programs in China and India, and expanding POC testing infrastructure. Growth is supported by government STI control initiatives and increasing adoption of molecular POC platforms. The region is also a manufacturing hub for rapid test kits, with domestic players gaining share. Direction: up.<\/p>\n
North America (estimated share: 30%)<\/p>\n
North America accounts for 30% of market value, with the United States as the single largest market due to high reimbursement rates, rapid adoption of CLIA-waived molecular tests, and strong public health focus on STI control. Growth is driven by home-testing expansion and digital connectivity, but tempered by regulatory costs and pricing pressure in public tenders. Direction: stable.<\/p>\n
Europe (estimated share: 20%)<\/p>\n
Europe holds a 20% share, with growth supported by national STI action plans and increasing screening recommendations. The EU IVDR transition is reshaping the competitive landscape, favoring well-capitalized suppliers. Germany, France, and the UK are key markets. Growth is moderate due to budget constraints and slower adoption of home-testing compared to North America. Direction: stable.<\/p>\n
Latin America (estimated share: 10%)<\/p>\n
Latin America represents 10% of the market, with growth driven by donor-funded programs and expanding public health screening in Brazil and Mexico. The shift from syndromic management to etiological diagnosis is boosting demand for rapid tests. Challenges include pricing pressure and logistical barriers in remote areas, but volume growth is strong. Direction: up.<\/p>\n
Middle East & Africa (estimated share: 5%)<\/p>\n
Middle East & Africa account for 5% of market value, with high growth potential from a small base. Demand is driven by donor-funded STI control programs, particularly in sub-Saharan Africa, where gonorrhea prevalence is high. The region relies heavily on lateral flow immunoassays due to cost constraints, but molecular POC adoption is increasing in urban centers. Direction: up.<\/p>\n
Market Outlook (2026-2035)<\/p>\n
In the baseline scenario, IndexBox estimates a 7.8% compound annual growth rate for the global rapid gonorrhea test kits market over 2026-2035, bringing the market index to roughly 210 by 2035 (2025=100).<\/p>\n
Note: indexed curves are used to compare medium-term scenario trajectories when full absolute volumes are not publicly disclosed.<\/p>\n
For full methodological details and benchmark tables, see the latest IndexBox Rapid Gonorrhea Test Kits market<\/a> report.<\/p>\n","protected":false},"excerpt":{"rendered":"Abstract According to the latest IndexBox report on the global Rapid Gonorrhea Test Kits market, the market enters…\n","protected":false},"author":2,"featured_media":91573,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[46118,27034,46120,1176,46121,46117,46119,46116,134,3804],"class_list":["post-91572","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-46118","tag-antimicrobial-resistance","tag-ct-ng","tag-diagnostics","tag-home-testing","tag-market-forecast","tag-point-of-care","tag-rapid-gonorrhea-test-kits","tag-roche","tag-sexual-health"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116808029710501391","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/91572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=91572"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/91572\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/91573"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=91572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=91572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=91572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}